GW Pharma (GWPH) Revenue Beats Consensus, PT to $222 at Oppenheimer

November 6, 2019 6:34 AM EST Send to a Friend
Oppenheimer analyst, Esther Rajavelu, reiterated her Outperform rating on shares of GW Pharma (NASDAQ: GWPH) and cut her price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login